Flavin mononucleotide.

Riboflavin taken orally is dephosphorylated in the gut before absorption, then rephosphorylated inside cells by riboflavin kinase using ATP to give FMN. Supplemental FMN follows the same route: it is hydrolysed to riboflavin at the brush border and reassembled intracellularly. So the two are not additive in any meaningful sense, they are the same nutrient at different points in one pathway. This is textbook vitamin B2 biochemistry.

Pyridoxine 5'-phosphate oxidase is an FMN-dependent flavoprotein, and without adequate FMN the conversion of pyridoxine and pyridoxamine phosphates to pyridoxal 5'-phosphate is impaired. This is a direct dependency, not a general nutrient synergy. It explains why B6 status can look poor in someone whose riboflavin status is inadequate. Supplying P5P directly bypasses the step.

MTHFR uses FAD as its cofactor, and FAD is made from FMN by FAD synthase. Riboflavin status therefore influences MTHFR activity, an effect that is more pronounced in people carrying the thermolabile 677TT variant of the enzyme. The relationship is between the flavin cofactor and folate cycling, not between two interchangeable supplements. It is one of the clearer nutrient-genotype interactions in the one-carbon field.

Flavin-dependent reductases participate in releasing iron from ferritin and in mobilising stored iron, and low riboflavin status has been described as blunting the response to iron repletion. The effect is on iron utilisation rather than on iron absorption at the transporter. This is a nutrient interdependency worth flagging when iron status fails to respond as expected. It is mechanistic and observational rather than an established dosing rule.

Kynurenine 3-monooxygenase in the tryptophan to niacin route is an FAD-dependent flavoprotein. Inadequate riboflavin therefore restricts endogenous niacin synthesis from dietary tryptophan, which is part of why B vitamin deficiencies historically travelled together. Preformed niacin sidesteps the step entirely. Straightforward cofactor dependency.

Regenerating reduced glutathione from its oxidised disulfide requires glutathione reductase, which carries FAD. The erythrocyte glutathione reductase activation coefficient is the standard functional test of riboflavin adequacy for exactly this reason. Poor flavin status means slower recycling of the cell's main thiol buffer. This is measurable biochemistry, not a marketing pairing.

Flavoproteins in fatty acid beta-oxidation pass electrons through electron transfer flavoprotein and ETF-ubiquinone oxidoreductase into the coenzyme Q pool of the respiratory chain. Both FAD and FMN sit in that chain, FMN specifically as the prosthetic group of complex I. The two therefore work in series on the same electron path rather than doing separate jobs. Read it as bioenergetic architecture, not as a stacking claim.

Xanthine oxidase and aldehyde oxidase each carry both a molybdenum cofactor and FAD in the same protein, so both trace nutrients are needed for a functional enzyme. A shortfall in either limits activity. This is structural rather than a dose-response synergy. It is a useful illustration that cofactor nutrients are not independent.

Mammalian thioredoxin reductase requires both a selenocysteine residue at its active site and an FAD prosthetic group, so the enzyme depends on adequate status of both nutrients. It sits alongside the glutathione system in cellular thiol redox control. Neither nutrient substitutes for the other. Structural cofactor dependency again, not a combination effect.

Zinc influences thiol redox status and the activity of several flavin-associated systems, but the relationship is indirect and not well quantified in people. It appears here because the two are routinely formulated together rather than because a specific dependency has been mapped. The honest position is that this is a formulation co-occurrence with a thin mechanistic thread. Nothing here supports a claim of combined benefit.